1135122-10-9

Basic information

• Product Name: ETHYL 4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXYLATE
• Synonyms: ETHYL 4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXYLATE;4,5,6,7-Tetrahydro-thiazolo[5,4-c]pyridine-2-carboxylic acid ethyl ester
• CAS NO: 1135122-10-9
• Molecular Formula: C9H12N2O2S
• Molecular Weight: 212.26878
• EINECS: -0
• Mol File: 1135122-10-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ETHYL 4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXYLATE(1135122-10-9)
• EPA Substance Registry System: ETHYL 4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXYLATE(1135122-10-9)

Safety Data

• Hazardous Substances Data: 1135122-10-9(Hazardous Substances Data)

Usage

General Description

Ethyl 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylate is a chemical compound with a molecular formula C11H14N2O2S. It is a heterocyclic compound that contains a thiazole ring and a pyridine ring. ETHYL 4,5,6,7-TETRAHYDROTHIAZOLO[5,4-C]PYRIDINE-2-CARBOXYLATE is primarily used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. Its structural properties make it valuable for the development of new drugs and potentially have applications in the fields of medicine and pharmacology. Additionally, its chemical structure makes it a useful building block in the discovery and development of new molecules with desired biological activities.

Upstream product

• 188869-05-8 tert-butyl 3-bromo-4-oxo-piperidine-1-carboxylate 
• 1053656-51-1 5-tert-butyl 2-ethyl 6,7-dihydro[1,3]thiazolo[5,4-c]pyridine-2,5(4H)-dicarboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 758685-72-2 5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxylic acid 

Relevant articles and documents

Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors

Factor Xa (fXa) is a crucial player in various thromboembolic disorders. Inhibition of fXa can provide safe and effective antithrombotic effects. In this study, a series of anthranilamide compounds were designed by utilizing structure-based design strategies. Optimization at P1 and P4 groups led to the discovery of compound 16g: a highly potent, selective fXa inhibitor with pronounced in vitro anticoagulant activity. Moreover, 16g also displayed excellent in vivo antithrombotic activity in the rat venous thrombosis (VT) and arteriovenous shunt (AV-SHUNT) models. The bleeding risk evaluation showed that 16g had a safer profile than that of betrixaban at 1 mg/kg and 5 mg/kg dose. Additionally, 16g also exhibited satisfactory PK profiles. Eventually, 16g was selected to investigate its effect on hypoxia-reoxygenation- induced H9C2 cell viability. MTT results showed that H9C2 cell viability can be remarkably alleviated by 16g.